Eupraxia Pharmaceuticals Inc.
EPRX
NASDAQ·Healthcare·Biotechnology·Mkt cap $281.2M
$8.40
▲ +12.00%
P/E
-8.48
Mkt Cap
$281.2M
52-Wk Range
$5.15–$9.32
52-Week Range
$5.15 - $9.32
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 59.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary EP-104 technology platform with multiple clinical applications
- Advanced Phase III clinical trial status for lead indication
- Focus on underserved patient populations with significant market opportunity
- Diversified pipeline reducing single-product risk
Bear Case
1 risk
- Above-average volatility (beta 1.5).
Growth
Stable outlook
Phase III trial completion and potential regulatory approval for knee osteoarthritis indication
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+40.2% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying EPRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 11, 2026
Reported EPS of -$0.23 vs -$0.25 consensus (+8.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+8.0%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · May 4, 2026
vs Industry
How EPRX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related